



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/535,711	02/07/2006	Barbara Bertani	P33150	7489
20462 7590 08/04/2008 SMITHKLINE BEECHAM CORPORATION CORPORATE INTELLECTUAL PROPERTY-US, UW2220 P. O. BOX 1539 KING OF PRUSSIA, PA 19406-0939				
EXAMINER				
HABTE, KAHISAY				
ART UNIT		PAPER NUMBER		
1624				
NOTIFICATION DATE		DELIVERY MODE		
08/04/2008		ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

US_cipkop@gsk.com

Office Action Summary

Application No.

10/535,711

Applicant(s)

BERTANI ET AL.

Examiner

Kahsay T. Habte

Art Unit

1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-22 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 1-22 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SF/88)
Paper No(s)/Mail Date ____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date ____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: ____

DETAILED ACTION

1. Claims 1-22 are pending in this application.

Election/Restrictions

2. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

6-{2-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]oxazin-3-one
6-{2-[4-(2,7-Dimethylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]oxazin-3-one
6-{2-[4-(7-Chloro-2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]oxazin-3-one
6-[2-(4-Quinolin-4-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]oxazin-3-one
6-{2-[4-(2-Methylquinazolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]oxazin-3-one
6-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]oxazin-3-one
6-{2-[4-(6-Methoxyquinolin-8-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]oxazin-3-one
6-[2-(4-Quinolin-8-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]oxazin-3-one
6-{2-[4-(1*H*-Indol-4-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]oxazin-3-one
6-{2-[4-(7-Chloro-2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-7-fluoro-4*H*-benzo[1,4]oxazin-3-one
4-Methyl-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]oxazin-3-one
6-[2-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]ethanoyl]-4*H*-benzo[1,4]oxazin-3-one
6-[1-Hydroxy-2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]-4*H*-benzo[1,4]oxazin-3-one
6-{2-[4-(2-Methyl-4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]oxazin-3-one

Art Unit: 1624

6-{2-[3-Methyl-4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one
6-{2-[2-Methyl-4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one
6-{2-[4-(2-Methylquinolin-5-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one
6-{2-[4-(2-Methylquinolin-5-yl)piperidin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one
6-{2-[4-(2-Methylquinolin-5-yl)-[1,4]diazepan-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one
6-{2-[4-(2-Methylquinazolin-5-yl)-[1,4]diazepan-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one
7-Fluoro-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one
6-{3-[4-(2-Methylquinolin-5-yl)-piperazin-1-yl]-propyl}-4H-benzo[1,4]-oxazin-3-one
6-{3-[4-(7-Fluoro-2-methylquinolin-5-yl)piperazin-1-yl]-propyl}-4H-benzo-[1,4]oxazin-3-one
6-{3-[4-(2-Methylquinolin-5-yl)-piperazin-1-yl]-propanoyl}-4H-benzo[1,4]-oxazin-3-one
6-[1-Hydroxy-3-[4-(2-methylquinolin-5-yl)-piperazin-1-yl]-propyl]-4H-benzo-[1,4]oxazin-3-one
6-{(E)-3-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]propenyl}-4H-benzo[1,4]-oxazin-3-one
6-[4-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]butyl]-4H-benzo[1,4]oxazin-3-one
6-[4-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]-cyclohex-1-enyl]-4H-benzo[1,4]-oxazin-3-one
6-[4-[4-(2-Methylquinazolin-5-yl)piperazin-1-yl]butyl]-4H-benzo[1,4]oxazin-3-one
6-{2-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]ethoxy}-4H-benzo[1,4]oxazin-3-one
4-Methyl-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethoxy}-4H-benzo[1,4]oxazin-3-one
7-Fluoro-6-{2-[4-(7-fluoro-2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one
6-{2-[4-(7-fluoro-2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one
7-Fluoro-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethanoyl}-4H-benzo[1,4]oxazin-3-one
6-[1-Hydroxy-2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]-4H-benzo[1,4]-oxazin-3-one

etc. See claim 12 for the complete list.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner:

The claims deemed to correspond to the species because of various definitions of A, X, q, R1, R2, and R3.

The following claim(s) are generic: claims 1 and 17.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the special technical feature of most of the species recited in claim 12 is different one from the other because of the various definitions of variables A, X and q.

A telephone call was made to Ms. Soma Simon on 07/28/2008 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

It is recommended that applicants limit the definition of A according to the elected species. In order to expedite prosecution, it is also recommended that applicants delete claims 19 and 21.

Conclusion

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kahsay Habte whose telephone number is (571) 272-0667. The examiner can normally be reached on M-F (9:00AM- 5:30PM).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached at (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300.

Art Unit: 1624

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Kahsay T. Habte/
Primary Examiner, Art Unit 1624

July 31, 2008